Register now for the 5th Annual Perspectives in Breast Cancer Care, September 12-13, 2025 and explore groundbreaking advancements in breast cancer treatment. Stay informed with the latest innovations shaping the future of breast cancer care and research.
An integrated intervention had the greatest impact in a randomized trial
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
About the survey This survey aims to evaluate oncologists’ attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in…
PHILADELPHIA (January 21, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Weiran Feng, PhD, as an Assistant Professor in the…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in…
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT])…
Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Tyler Zemla , Susan Geyer , Michael Knopp , Spencer Behr ,…
